Roivant Sciences Common Stock, Shares, Outstanding increased by 2.9% to $709.69M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 1.4%, from $719.63M to $709.69M. Over 4 years (FY 2020 to FY 2024), Common Stock, Shares, Outstanding shows relatively stable performance with a 1.7% CAGR.
A decrease indicates share buybacks, which can boost EPS, while an increase suggests equity issuance, which may dilute existing shareholders.
This is the total number of common shares held by all shareholders, excluding treasury shares. It is the primary denomin...
Standardized metric used globally to assess equity dilution and ownership structure.
other_common_stock_shares_outstanding| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $222.67M | $684.79M | $692.01M | $694.98M | $701.17M | $704.39M | $726.80M | $760.14M | $767.14M | $800.79M | $804.89M | $806.68M | $739.05M | $733.33M | $719.63M | $695.94M | $682.23M | $689.70M | $709.69M |
| QoQ Change | — | +207.5% | +1.1% | +0.4% | +0.9% | +0.5% | +3.2% | +4.6% | +0.9% | +4.4% | +0.5% | +0.2% | -8.4% | -0.8% | -1.9% | -3.3% | -2.0% | +1.1% | +2.9% |
| YoY Change | — | — | — | — | +214.9% | +2.9% | +5.0% | +9.4% | +9.4% | +13.7% | +10.7% | +6.1% | -3.7% | -8.4% | -10.6% | -13.7% | -7.7% | -5.9% | -1.4% |